由於美國股指期貨在週三早盤略微下跌，今天可能吸引投資者關注的一些股票如下：
<ul>
<li>UiPath Inc. (NYSE: PATH) 的股票在週二的盤後交易中上漲，此前宣佈該公司將加入標準普爾中型股 400 指數。在週二市場收盤後，標準普爾道瓊斯指數宣佈，智能自動化公司 UiPath 將於 2026 年 1 月 2 日市場開盤前取代 Synovus Financial Corp. (NYSE: SNV)，成為標準普爾中型股 400 指數的一部分。UiPath 的股票在盤後交易中上漲 6.8%，至 17.05 美元。</li>
<li>Agios Pharmaceuticals Inc. (NASDAQ: AGIO) 披露美國 FDA 已批准 AQVESME™（米塔匹伐）用於治療成人α或β地中海貧血。Agios Pharmaceuticals 的股票在週二下跌 1.4%，收於 24.59 美元。</li>
<li>Can Fite Biopharma (NYSE: CANF) 披露進行 1 拆 3,000 的反向股票拆分。Can Fite Biopharma 的股票在盤後交易中下跌 28.8%，至 0.17 美元。</li>
</ul>
查看我們的 盤前報道
<ul>
<li>Citius Pharmaceuticals Inc. (NASDAQ: CTXR) 報告第四季度業績超出預期。該公司每股虧損 11 美分，而市場預期為每股虧損 43 美分。Citius Pharmaceuticals 的股票在盤後交易中上漲 22.1%，至 1.27 美元。</li>
<li>Ramaco Resources Inc. (NASDAQ: METC) 報告了一項 1 億美元的股票回購計劃。Ramaco Resources 的股票在盤後交易中上漲 7.1%，至 18.09 美元。</li>
</ul>
看看這個：
<ul>
<li>吉姆·克萊默看好這隻科技股：‘繼續持有’</li>
</ul>
照片：Ian Dewar Photography / Shutterstock

METCB

METC

PATH

UiPath 加入標準普爾中型股 400 指數，股價上漲 6.8%。Agios 獲得 FDA 對 AQVESME™的批准，股價下跌 1.4%。Can Fite Biopharma 宣佈進行 1 股換 3,000 股的反向拆分，股價下跌 28.8%。Citius Pharmaceuticals 超出盈利預期，股價上漲 22.1%。Ramaco Resources 公佈 1 億美元的股票回購計劃，股價上漲 7.1%。美國股指期貨略微下跌

With U.S. stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<div class="lb-trans">由於美國股指期貨在週三早盤略微下跌，今天可能吸引投資者關注的一些股票如下：
</div><ul>
<li>UiPath Inc. (NYSE: PATH) shares gained in extended trading on Tuesday after it was announced that the company will join the S&amp;P Midcap 400. After the market closed on Tuesday, S&amp;P Dow Jones Indices announced that agentic automation company UiPath will replace Synovus Financial Corp. (NYSE: SNV) in the S&amp;P MidCap 400, effective before the market open on Jan. 2, 2026, according to Benzinga Pro. UiPath shares climbed 6.8% to $17.05 in after-hours trading.</li>
<li>Agios Pharmaceuticals Inc. (NASDAQ: AGIO) disclosed that the US FDA has approved AQVESME™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia. Agios Pharmaceuticals shares fell 1.4% to close at $24.59 on Tuesday.</li>
<li>Can Fite Biopharma (NYSE: CANF) disclosed a 1-for-3,000 reverse share split. Can Fite Biopharma’s shares dipped 28.8% to $0.17 in the after-hours trading session.</li>
</ul>
<div class="lb-trans"><ul>
<li>UiPath Inc. (NYSE: PATH) 的股票在週二的盤後交易中上漲，此前宣佈該公司將加入標準普爾中型股 400 指數。在週二市場收盤後，標準普爾道瓊斯指數宣佈，智能自動化公司 UiPath 將於 2026 年 1 月 2 日市場開盤前取代 Synovus Financial Corp. (NYSE: SNV)，成為標準普爾中型股 400 指數的一部分。UiPath 的股票在盤後交易中上漲 6.8%，至 17.05 美元。</li>
<li>Agios Pharmaceuticals Inc. (NASDAQ: AGIO) 披露美國 FDA 已批准 AQVESME™（米塔匹伐）用於治療成人α或β地中海貧血。Agios Pharmaceuticals 的股票在週二下跌 1.4%，收於 24.59 美元。</li>
<li>Can Fite Biopharma (NYSE: CANF) 披露進行 1 拆 3,000 的反向股票拆分。Can Fite Biopharma 的股票在盤後交易中下跌 28.8%，至 0.17 美元。</li>
</ul>
</div>Check out our premarket coverage here
<div class="lb-trans">查看我們的 盤前報道
</div><ul>
<li>Citius Pharmaceuticals Inc. (NASDAQ: CTXR) reported better-than-expected earnings for the fourth quarter. The company posted a quarterly loss of 11 cents per share, compared to market estimates of a loss of 43 cents per share. Citius Pharmaceuticals shares surged 22.1% to $1.27 in after-hours trading.</li>
<li>Ramaco Resources Inc. (NASDAQ: METC) reported a $100 million stock repurchase plan. Ramaco Resources shares jumped 7.1% to $18.09 in the after-hours trading session.</li>
</ul>
<div class="lb-trans"><ul>
<li>Citius Pharmaceuticals Inc. (NASDAQ: CTXR) 報告第四季度業績超出預期。該公司每股虧損 11 美分，而市場預期為每股虧損 43 美分。Citius Pharmaceuticals 的股票在盤後交易中上漲 22.1%，至 1.27 美元。</li>
<li>Ramaco Resources Inc. (NASDAQ: METC) 報告了一項 1 億美元的股票回購計劃。Ramaco Resources 的股票在盤後交易中上漲 7.1%，至 18.09 美元。</li>
</ul>
</div>Check This Out:
<div class="lb-trans">看看這個：
</div><ul>
<li>Jim Cramer Is Bullish On This Tech Stock: ‘Continue To Own It’</li>
</ul>
<div class="lb-trans"><ul>
<li>吉姆·克萊默看好這隻科技股：‘繼續持有’</li>
</ul>
</div>Photo: Ian Dewar Photography / Shutterstock
<div class="lb-trans">照片：Ian Dewar Photography / Shutterstock
</div>

UiPath、Ramaco Resources 和另外三隻股票值得在週三關注